Protein CC16

PreclinicalSmall molecule

UUniversity Hospital, Clermont-Ferrand

Protein CC16 is one of 8 small molecule programs targeting Acute Bronchiolitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute BronchiolitisActive, not recruiting

Acute BronchiolitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Acute Bronchiolitis

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

3 2

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

1 3

Adrenaline

AARS Pharmaceuticals, Inc.

Phase 3

1 4

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 2

1 5

Singulair

AstraZeneca

Preclinical

1 6

Singulair

OOrganon and Co

Preclinical

1 7

Dexamethasone 12

AAssiut University

Phase 1

1 8

Protein CC16

UUniversity Hospital, Clermont-Ferrand

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Bronchiolitis1 trial

Acute Bronchiolitis and Severity Markers: Interest in Protein CC16

Unknown status·UUniversity Hospital, Clermont-Ferrand·N/A·NCT02984046·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Protein CC16. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Protein CC16 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Protein CC16. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Clermont-Ferrand company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Clermont-Ferrand

Protein CC16

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Bronchiolitis1 trial

References

Drug Info

Quick Facts

Related News